US20070160699A1 - Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof - Google Patents

Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof Download PDF

Info

Publication number
US20070160699A1
US20070160699A1 US10/587,286 US58728605A US2007160699A1 US 20070160699 A1 US20070160699 A1 US 20070160699A1 US 58728605 A US58728605 A US 58728605A US 2007160699 A1 US2007160699 A1 US 2007160699A1
Authority
US
United States
Prior art keywords
extract
liver
dulcis thunb
hovenia dulcis
kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/587,286
Inventor
Kiyoung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2004-0006435A external-priority patent/KR100536856B1/en
Priority claimed from KR1020040006437A external-priority patent/KR100586269B1/en
Priority claimed from KR10-2004-0006436A external-priority patent/KR100536855B1/en
Application filed by Individual filed Critical Individual
Publication of US20070160699A1 publication Critical patent/US20070160699A1/en
Priority to US12/465,830 priority Critical patent/US7846484B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals

Definitions

  • the present invention relates to a composition
  • a composition comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof as an effective ingredient.
  • liver disease is caused by liver damage resulted from chronic fatigue by stress and most of exogeneous substances.
  • the development rate of liver disease in Korea is very high, comparing to foreign countries, and in particular, the death rate of liver cancer is the top in the world and the death rate of chronic liver disease is the third.
  • liver disease is the leading cause of death of adults at the age of 40s in Korea.
  • the most fatal disease is viral hepatitis in Korea.
  • the death by liver cirrhosis is 5 ⁇ 10 fold higher than that by viral hepatitis in Western countries.
  • Liver is the organ that shows the most active metabolism among many human organs. Acute or chronic damage in liver by in variety of reasons such as fatty diet, heavy drinking of alcohol, virus infection, poisons including chemicals, mal-nutrition, etc, might be developed into serious conditions like fatty liver, hepatitis, jaundice, hepatic cirrhosis and liver cancer. Particularly, fatty diet and heavy drinking of alcohol cause fatty liver, that is, lipid is accumulated in liver tissues. At this time, GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transaminase) and -GTP ( -glutamyl transpeptidase) increase in serum. Since liver has great buffer capacity, liver disease hardly shows symptoms in early stage, and only when it gets serious, it shows symptoms.
  • Liver has functions of preservation and circulation of blood, regulation of blood flow and detoxification, and is also known to be involved in mental activity.
  • Human bodies are exposed on pollutions and lots of poison according to industrialization, so that the liver has to overwork in order to counteract poison.
  • Liver damage by mental stress is worse. If human mind gets rest, damaged liver cells are recovered. The thing is that there is no extra time for rest for modern citizens. So, excessive mental stress, heavy smoke and alcohol drinking make liver damage worse, resulting in mal-function of detoxification, that is mal-function of immune system, which might be a cause of another disease.
  • Liver cirrhosis is caused by fibrosis of liver tissues, which is the condition of losing homeostasis between generation and degeneration of connective tissue. That is, connective tissue is over-accumulated in liver tissues, accompanying necrosis or inflammation. Fibrosis of liver tissues is progressed by the excessive generation of connective tissue resulted from the growth and transfer of hepatic stellate cells (HSCs) transformed in the form of myofibroblasts (Gressner et al., Biochem. Biophys. Res. Commun. 151 ⁇ 222, 1988).
  • HSCs hepatic stellate cells
  • Liver cirrhosis is the final stage of every chronic liver diseases, by which liver loses its general functions rapidly with showing the decrease of hepatic blood flow, the reduction of blood flow in liver, mal-function of metabolizing enzyme, qualitative and quantitative changes in blood protein, variation of bile flux, etc.
  • Hepatotoxicity inducers are exemplified by carbon tetrachloride (CCl 4 ), D-galactosamine, lipopolysaccharide (LPS) and bromobenzene, and in particular, carbon tetrachloride is known to induce hepatotoxicity by inducting lipid peroxidation of liver cells (Recknagel et al., Pharmacol. Rev. 19:145-208, 1967; Alpers et al., Mol. Pharmacol. 4:566-573, 1968; Slater T. F., Biochem. J. 222: 1 ⁇ 15, 1994). Carbon tetrachloride is a hepatotoxicity inducer that has been used to investigate anti-hepatotoxic activity.
  • Anti-oxidation not only inhibits or prevents lipid peroxidation but also has liver protective and anti-inflammatory effects.
  • an antioxidant compound has been used for the protection of liver and liver cells against attacks by reactive oxygen intermediate.
  • Antioxidant agents separated from natural resources such as flavonoid, quercetin, silymarin or vitamin E have been reported to have positive effect on lipid peroxidation and hepatic fibrosis.
  • N-acetylcysteine (NAC) has been confirmed to reduce oxidative stress and hepatic fibrosis in the early stage of hepatic fibrosis by its anti-oxidative activity.
  • Picrorhiza Kurroa (kutkin) is another natural anti-oxidative compound that has liver protective and anti-fibrosis effects by reducing damage caused by lipid peroxidation and free radical.
  • liver cell reproduction stimulator and/or liver function protector such as ursodeoxycholic acid, silymarin ( Biotech. Therapeutics, 4, 263-270, 1993), DDB (biphenyl dimethyl dicarboxylate; Biochem. Biophy. Res.
  • liver disease is developed not by just one reason but by co-work of many factors. Thus, one medicine having a certain function is not enough for the treatment of every kinds of liver disease.
  • the conventional medicine for the treatment of liver diseases has problems of unexpected reaction and other side effects by long-term or mass administration.
  • kidney has functions of regulating the concentrations of ion and body fluids, urinating waste products (urea, uric acid, creatinine, etc) and eliminating toxic substances, drugs and metabolites out of the system after counteracting poison.
  • superoxide dismutase catalizing lipid peroxidation has been known to be involved in recovery from cell damage (Slater T F. Biochem. J., 222, 1-15, 1994; Esterbauer H, Schauer R J, Zollner H., 1994; Free Radical Biology & Medicine 11, 81-128, 1992).
  • alkaline phosphatase (ALP) and blood urea nitrogen (BUN) are also in use as diagnostic indices for kidney functions.
  • BUN blood urea nitrogen
  • GFR glomerular filtration rate
  • Prerenal azotemia means kidney mal-function without kidney damage, which is resulted from hypoperfusion by congestive heart failure, shock, hypovolemia and hemorrhage.
  • postrenal azotemia is caused when the flow of urine is blocked in the lower part of kidney. In the case of postrenal azotemia, full recovery is expected by the elimination of the cause.
  • uremia When azotemia accompanies various clinical symptoms and biochemical disorders, it is called uremia.
  • uremia is not only a simple biochemical disorder but also a syndrome carrying metabolic disorders, endocrine disorders, gastrointestinal disorders, neuromuscular disorders and cardiovascular disorders, in addition to elimination disorders.
  • Diseases caused by mal-function of kidney are exemplified by acute pyelonephritis, chronic pyelonephritis, renal tuberculosis, UTI, urinary stone, renal cell cancer, etc.
  • Hovenia dulcis Thunb. is a kind of deciduous broad-leaved tall tree belonging to Rhamnaceae, which is also called ‘Jigumok’ in Chinese medicine.
  • Hovenia dulcis Thunb. in Bon-cho-kang-mok that it tastes sweet and plain, has no toxicity, makes the five viscera (heart, liver, spleen, lungs and kidneys) work smooth and easy, eliminates fever in the chest, quenches thirst, neutralizes alcohol poisoning, relieves vomiting, detoxificates insect poison and might treat five types of hemorrhoids. It has also been known to have liver protective effect.
  • Lindera obstiloba is a kind of deciduous broad-leaved tall tree belonging to Lauraceae, which is distributed widely in Korea, Japan, China and Manchuria.
  • the flowers, leaves and stems of Lindera obstiloba emit unique fragrance.
  • the stems of it have been used for medicinal purposes, owing to their anti-bacterial effect.
  • Fresh shoots of it have been used for tea.
  • It is an object of the present invention to provide a composition comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof as an effective ingredient.
  • the present invention provides a compound comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof as an effective ingredient.
  • the composition of the present invention includes an anti-oxidative composition, an anti-fibrosis composition, a liver function improving composition and a kidney function improving composition.
  • the extracting method for Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention is as follows.
  • Hovenia dulcis Thunb or Lindera obstiloba is washed with water and then dried in the shadow.
  • the dried Hovenia dulcis Thunb or Lindera obstiloba is put in a reflex extractor, to which purified water is added and heated at 10° C. for 90 minutes, leading to hot water extraction.
  • the hot water extract is filtered with a filter paper under reduced pressure when it is still hot.
  • the filtrate is concentrated by using a vacuum evaporator.
  • the solution is dried by using a freeze dryer.
  • the stems, flowers, leaves and seeds of Hovenia dulcis Thunb or Lindera obstiloba are all available in the present invention.
  • composition rate of herbs for the composition of the present invention is determined based on the dry weight of each herb. Precisely, Hovenia dulcis Thunb and Lindera obstiloba are mixed at the ratio of 3:2 ⁇ 1:1, and more preferably mixed at the ratio of 2:1 ⁇ 1:1. Such ratio is determined under the consideration of effective dosage of each herb and side effects of it, and the pharmaceutical effects are dropped rapidly or side effects might be a problem when the ratio is out of the above range.
  • GOT, GPT, ALP, BUN and total bilirubin which are all liver function indices, are all lowered in the group administered with Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof, indicating that the extract of the present invention has excellent liver function improving effect.
  • ALP and BUN are not only used as liver function indices but also used as kidney function indices.
  • the lowered levels of ALP and BUN indicate that Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention has excellent kidney function improving effect, as well.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention reduces the amount of hydroxyproline in liver tissues but increases that in kidney tissues, indicating that the extract of the invention has excellent anti-fibrosis and kidney protective effects.
  • the herbal extract extracted from the mixture of Hovenia dulcis Thunb and Lindera obstiloba shows higher effects than each individual extract, that is the mixture extract reduces hydroxyproline in liver tissues more but increases it in kidney tissues more than each individual extract.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention can reduce the level of malondialdehyde, an index for lipid peroxidation in liver and kidney tissues, indicating that the extract of the invention has excellent anti-oxidative effect.
  • Liver cell line and kidney cell line treated with Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention show high cell viability, indicating that the extract of the present invention has excellent liver cell and kidney cell protective effects.
  • composition of the present invention can be effectively used for the improvement and the protection of liver and kidney functions and for anti-oxidation and anti-fibrosis as well.
  • composition of the present invention can additionally include, in addition to Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof, one or more effective ingredients having the same or similar functions to the extract of the present invention.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention can be administered orally or parenterally and be used in general forms of pharmaceutical formulation.
  • the herbal mixture extract of the present invention can be prepared for oral or parenteral administration by mixing with generally used fillers, extenders, binders, wetting agents, disintegrating agents, diluents such as surfactant, or excipients.
  • Solid formulations for oral administration are tablets, pills, dusting powders, granules and capsules. These solid formulations are prepared by mixing one or more suitable excipients such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.
  • Liquid formulations for oral administration are suspensions, solutions, emulsions and syrups, and the above-mentioned formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives in addition to generally used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions, emulsions, freeze-drying agent and suppositories.
  • Water insoluble excipients and suspensions can contain, in addition to the active compound or compounds, propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc.
  • Suppositories can contain, in addition to the active compound or compounds, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin, etc.
  • the dosage units can contain, for example, 1, 2, 3 or 4 individual doses or 1 ⁇ 2, 1 ⁇ 3 or 1 ⁇ 4 of an individual dose.
  • An individual dose preferably contains the amount of active compound which is administered in one application and which usually corresponds to a whole, 1 ⁇ 2, 1 ⁇ 3 or 1 ⁇ 4 of a daily dose.
  • the effective dosage of Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention is 200 ⁇ 600 mg/kg, respectively, and more preferably 300 ⁇ 400 mg/kg, and the administration times are 1 ⁇ 6 times a day.
  • composition of the present invention can be administered singly or combination with surgical operation, radiotherapy, hormone therapy, chemotherapy and biological reaction regulator, to improve liver and kidney functions and to obtain anti-oxidative and anti-fibrosis effects.
  • the composition of the present invention can be added in health food to improve liver and kidney functions and to obtain anti-oxidative and anti-fibrosis effects.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention can be added as it is or after being mixed with other food or ingredients, according to the conventional method.
  • the mixing ratio of effective ingredients is determined by the purpose of use (prevention, health or therapeutic treatment).
  • the extract is preferably added by under 15 weight %, more preferably under 10 weight %, to the raw material.
  • the content of the extract might be less than the above when it is administered for long-term to improve health conditions but the effective dosage could contain more than the above amount because the extract of the invention is very safe.
  • Health beverages comprising the composition of the present invention can additionally include various flavors or natural carbohydrates, etc, like other beverages.
  • the natural carbohydrates above can be one of monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xilytole, sorbitol and erythritol.
  • a sweetener either natural sweetener such as thaumatin and stevia extract or artificial sweetener such as saccharin and aspartame can be used.
  • the ratio of natural carbohydrate to the composition of the present invention is preferably 0.01 ⁇ 0.04 g to 100 ml, more preferably 0.02 ⁇ 0.03 g to 100 ml.
  • the composition of the present invention can include in variety of nutrients, vitamines, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, arginic acid and its salts, organic acid, protective colloidal viscosifiers, pH regulators, stabilizers, antiseptics, glycerin, alcohols, carbonators which used to be added to soda, etc.
  • the composition of the present invention can also include natural fruit juice, fruit beverages and/or fruit flesh addable to vegetable beverages. All the mentioned ingredients can be added singly or together. The mixing ratio of those ingredients does not matter in fact, but in general, each can be added by 0.01 ⁇ 0.1 weight part per 100 weight part of the composition of the invention.
  • Hovenia dulcis Thunb was washed with water and then dried in the shadow. 20 g of the dried Hovenia dulcis Thunb was put in a reflex extractor, to which 1.5 l of purified water was added and was heated at 100° C. for 90 minutes. The hot water extract was filtered with a filter paper under the reduced pressure when it was still hot. The filtrate was concentrated by using a vacuum evaporator. It was dried by a freeze dryer for long-term storage.
  • the concentrated solution was used for animal test (2 ml/rat/day).
  • Lindera obstiloba extract was prepared in analogy to the procedure as described above in example 1.
  • the concentrated solution was used for animal test (2 ml/rat/day).
  • the concentrated solution was used for animal test (2 ml/rat/day), and 4-fold concentrated solution was used for MTT and NR assay (50 ⁇ l/well).
  • the animals were adapted to the test room for 2 weeks, and then divided into 5 groups; ⁇ circle around (1) ⁇ normal group, ⁇ circle around (2) ⁇ CCl 4 treating group, ⁇ circle around (3) ⁇ CCl 4 +herbal mixture extract treating group, ⁇ circle around (4) ⁇ CCl 4 +Hovenia dulcis Thunb extract treating group and ⁇ circle around (5) ⁇ CCl 4 +Lindera obstiloba extract treating group. Each group was composed of 10 rats.
  • mice were administered with olive oil and CCl 4 mixture by 1 ml/rat/day, three times a week for 4 weeks so as to induce liver fibrosis (cirrhosis) and kidney damage.
  • CCl 4 treating group was administered orally with distilled water by 2 ml/rat/day
  • CCl 4 +herbal mixture extract treating group was administered orally with the herbal mixture extract prepared in the above example 3 by 2 ml/rat/day
  • CCl 4 +Hovenia dulcis Thunb extract treating group was administered orally with Hovenia dulcis Thunb extract prepared in the above example 1 by 2 ml/rat/day
  • CCl 4 +Lindera obstiloba extract treating group was administered orally with Lindera obstiloba extract prepared in the above example 2 also by 2 ml/rat/day.
  • Rats in every group including the normal group were weighed, and then anesthetized by ether. Blood was taken from heart by heart puncture, which was left at room temperature for over 2 hours. Then, centrifugation was performed at 3000 rpm for 10 minutes to obtain serum, which was stored at ⁇ 20° C. The serum was examined to measure the level of GOT, GPT, alkaline phosphatase, BUN and total bilirubin.
  • Liver and kidney of a rat which were already damaged by artificial inducement, were extracted and washed with phosphate buffer (pH 7.0), followed by measuring the weight. A part of liver and kidney tissues were kept at ⁇ 75° C. for the use of measuring hydroxyproline and malondialdehyde (MDA).
  • MDA hydroxyproline and malondialdehyde
  • 500 ⁇ l of AST substrate solution was put in two falcon tubes, which were heated at 37° C. for 3 ⁇ 5 minutes.
  • the substrate solution was diluted with standard solution in one tube, and in the other tube, 100 ⁇ l of serum sample was added. Reaction was induced in both tubes at 37° C. for 60 minutes.
  • 100 ⁇ l of purified water and 500 ⁇ l of coloring solution (2,3-dinitrophenylhydrazine) were added to each tube, which were then left at room temperature for 20 minutes. 5 ml of 0.4 N NaOH was added to each tube, followed by reaction at room temperature for 10 minutes. OD was measured at 505 nm.
  • ALT substrate solution 150 ⁇ l of ALT substrate solution was put in two falcon tubes, which were heated at 37° C. for 4 minutes.
  • the substrate solution was diluted with standard solution in one tube, and in the other tube, 100 ⁇ l of serum sample was added and reaction was induced at 37° C. for 30 minutes in both tubes.
  • 100 ⁇ l of purified water and 500 ⁇ l of coloring solution (2,3-dinitrophenylhydrazine) were added to each tube, which was left at room temperature for 20 minutes.
  • 1.5 ml of 0.4 N NaOH was added to each test tube, followed by reaction at room temperature for 10 minutes.
  • OD was measured at 505 nm.
  • ALP substrate buffer sodium-2-phenylphosphate
  • 50 ⁇ l of serum sample, 50 ⁇ l of purified water and 50 ⁇ l of standard solution were added to test tubes respectively, followed by reaction at 37° C. for 15 minutes.
  • 2.0 ml of coloring reagent was added to each test tube and then left at room temperature for 10 minutes. OD was measured at 570 nm within 60 minutes.
  • the levels of GOT, GPT, ALP, BUN and total bilirubin, which are liver function indices, were significantly low in experimental groups treated with Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention respectively, comparing to a control.
  • the level of those indices in the group treated with herbal mixture extract was the lowest.
  • ALP and BUN are the indices not only for the liver function but also for the kidney function, so that the lowered levels of ALP and BUN by the extract of the invention also mean that Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention have excellent kidney function improving effect as well.
  • liver (or kidney) tissues which were frozen or freeze-dried ( ⁇ 50° C., 72 hours) were distributed in a 10 ml glass bottle. 4 ml of 6 N HCl was put in the bottle, followed by homogenization with a homogenizer. Then, hydrolysis was performed in a dry oven at 110° C. for 10 ⁇ 24 hours, followed by filtering with a Whatmann filter paper. Likewise, standard solution which was diluted with trans-hydroxyproline 6 N HCl at different concentrations of 0, 0.2, 0.4, 0.6, 0.8 and 1.0 ⁇ g/50 ⁇ l was also hydrolyzed at 110° C. for 12 ⁇ 14 hours.
  • Homogenized tissue sample [0.2 g of liver tissues (or kidney tissues) in 1.8 ml of 1.15% KCl] and 200 ⁇ l of diluted standard material (0, 4, 8, 16, 32 nmol/200 ⁇ l tetramethoxypropane) were put together in falcon tube. 200 ⁇ l of standard solution diluted with sample was mixed with 100 ⁇ l of 0.2% SDS, followed by reaction at room temperature for 10 minutes. 750 ⁇ l of 20% acetic acid and 750 ⁇ l of 0.8% thiobarbiturate were added thereto. The solution was reacted at 95° C. for 30 minutes, then cooled down in ice. Upon completion of cooling down, 2 ml of n-butanol was added, followed by centrifugation to obtain supernatant. OD of the supernatant was measured at 532 nm by a spectrophotometer.
  • NCTC clone 1469 liver cell line
  • vero kidney cell line
  • KCLB Korea Cell Line Bank
  • MTT powder 5 mg was dissolved in 1 ml of phosphate buffer, which was stirred well and then filtered by 0.4 ⁇ m filter, resulting in MTT storage solution.
  • NR powder 4 mg was dissolved in 1 ml of tertially distilled water, which was then stirred well and filtered by 0.4 ⁇ m filter, resulting in NR storage solution.
  • Trypsin-EDTA containing 0.5% trypsin and 5.3 mM EDTA was purchased and 10-fold diluted with PBS before use.
  • MTT dye 50 ⁇ l/ml of storage solution+950 ⁇ l of medium
  • 50 ⁇ l/ml of MTT dye 50 ⁇ l of storage solution+950 ⁇ l of medium
  • 100 ⁇ l of DMSO was added, followed by stirring for 10 minutes.
  • OD was measured at 540 nm with ELISA reader.
  • the 96 well plate was taken to remove medium. 10 ⁇ l/ml of NR dye (10 ⁇ l of storage solution+990 ⁇ l of medium) was added to dilute the solution, which was distributed in each well by 200 ⁇ l, followed by further culture in a 37° C., 5% CO 2 incubator for 3 hours. After eliminating the medium, the plate was washed with 100 ⁇ l of 1% CaCl 2 and 0.5% formaldehyde. Supernatant was removed. Then, 200 ⁇ l of 1% acetic acid and 50% ethanol was added, followed by stirring for 10 minutes. OD was measured at 540 nm with ELISA reader.
  • Lindera obstiloba extract and herbal mixture extract of the present invention showed high cell viability in liver cell line.
  • herbal mixture extract is more effective to increase cell viability in liver cell line than Hovenia dulcis Thunb extract.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention did not harm cell viability in kidney cell line.
  • compositions comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention were prepared as follows.
  • Spices and condiments for health improvement that contains Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention by 20 ⁇ 95 weight % were prepared.
  • Tomato ketchup or source for health improvement was prepared by adding Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention by 0.2 ⁇ 1.0 weight % to tomato ketchup or source.
  • Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention was added to flour by 0.5 ⁇ 5.0 weight %, and the mixture was used to prepare bread, cake, cookies, cracker and noodles to produce health improving foods.
  • Health improving processed meat, noodle soups and gravies were prepared by adding Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention by 0.1 ⁇ 5.0 weight % to soups and gravies.
  • Health improving ground beef was prepared by adding Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention by 10 weight % to ground beef.
  • Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention was added to milk by 5 ⁇ 10 weight %, which was then used for the production of health improving dairy products including butter and ice cream.
  • Brown rice, barley, glutinous rice and Job's tears were gelatinized, dried and roasted by the conventional method, followed by pulverization with a pulverizer, resulting in 60-mesh granules.
  • Black bean, black sesame, Perilla japonica were steamed, dried and roasted by the conventional method, followed by pulverization with a pulverizer, resulting in 60-mesh granules.
  • Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention was concentrated under reduced pressure in a vacuum concentrator, and then dried by spray dryer. The dried product was pulverized into 60-mesh granules.
  • Crops, seeds and the dried powder of Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) were mixed by the following ratio.
  • Crops (brown rice 30 weight %, job's tears 15 weight %, barley 20 weight %)
  • Optional ingredients such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%) and Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) were mixed evenly. After pasteurization, the mixture was put in small container such as pet or glass bottle, resulting in the preparation of health beverages.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention is highly effective for the improvement of liver functions since it can lower the level of GOT, GPT, ALP, BUN and total bilirubin, which are major liver function indices.
  • ALP and BUN are also used as kidney function indices, so the decrease of the level of ALP and BUN by the extract of the present invention indicates that Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the invention can improve kidney functions as well.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention also can lower the amount of hydroxyproline in liver but increase the amount of hydroxyproline in kidney, suggesting that the extract above has excellent anti-fibrosis and kidney protecting effects.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention can lower the level of malondialdehyde, an index of lipid peroxidation in liver and kidney tissues, suggesting that the extract has excellent anti-oxidative effect.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention promotes cell viability in liver and kidney cell lines, indicating that the extract has excellent liver and kidney cell protective effects.
  • composition of the present invention can be effectively used not only for anti-oxidation and anti-fibrosis but also for the protection and the improvement of liver and kidney functions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition comprising Hovenia dulcis Thunb extract, Lindera obtusiloba extract or herbal mixture extract thereof as an effective ingredient.
Hovenia dulcis Thunb extract, Lindera obtusiloba extract or herbal mixture extract thereof of the present invention is highly effective for the improvement of liver functions since it can lower the level of GOT, GPT, ALP, BUN and total bilirubin, which are major liver function indices. ALP and BUN are also used as kidney function indices, so the decrease of the level of ALP and BUN by the extract of the present invention indicates that Hovenia dulcis Thunb extract, Lindera obtusiloba extract or herbal mixture extract thereof of the invention can improve kidney functions as well.
Hovenia dulcis Thunb extract, Lindera obtusiloba extract or herbal mixture extract thereof of the present invention also can lower the amount of hydroxyproline in liver but increase the amount of hydroxyproline in kidney, suggesting that the extract above has excellent anti-fibrosis and kidney protecting effects.
In addition, Hovenia dulcis Thunb extract, Lindera obtusiloba extract or herbal mixture extract thereof of the present invention can lower the level of malondialdehyde, an index of lipid peroxidation in liver and kidney tissues, suggesting that the extract has excellent anti-oxidative effect.
Hovenia dulcis Thunb extract, Lindera obtusiloba extract or herbal mixture extract thereof of the present invention promotes cell viability in liver and kidney cell lines, indicating that the extract has excellent liver and kidney cell protective effects. Therefore, the composition of the present invention can be effectively used not only for anti-oxidation and anti-fibrosis but also for the protection and the improvement of liver and kidney functions.

Description

    TECHNICAL FIELD
  • The present invention relates to a composition comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof as an effective ingredient.
    • BACKGROUND ART
  • As one of representative adult diseases, liver disease is caused by liver damage resulted from chronic fatigue by stress and most of exogeneous substances. The development rate of liver disease in Korea is very high, comparing to foreign countries, and in particular, the death rate of liver cancer is the top in the world and the death rate of chronic liver disease is the third. According to a recent report from National Statistical Office, Korea, liver disease is the leading cause of death of adults at the age of 40s in Korea. Among many liver diseases, the most fatal disease is viral hepatitis in Korea. In the meantime, the death by liver cirrhosis is 5˜10 fold higher than that by viral hepatitis in Western countries.
  • Liver is the organ that shows the most active metabolism among many human organs. Acute or chronic damage in liver by in variety of reasons such as fatty diet, heavy drinking of alcohol, virus infection, poisons including chemicals, mal-nutrition, etc, might be developed into serious conditions like fatty liver, hepatitis, jaundice, hepatic cirrhosis and liver cancer. Particularly, fatty diet and heavy drinking of alcohol cause fatty liver, that is, lipid is accumulated in liver tissues. At this time, GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transaminase) and
    Figure US20070160699A1-20070712-P00900
    -GTP (
    Figure US20070160699A1-20070712-P00900
    -glutamyl transpeptidase) increase in serum. Since liver has great buffer capacity, liver disease hardly shows symptoms in early stage, and only when it gets serious, it shows symptoms.
  • Liver has functions of preservation and circulation of blood, regulation of blood flow and detoxification, and is also known to be involved in mental activity. Human bodies are exposed on pollutions and lots of poison according to industrialization, so that the liver has to overwork in order to counteract poison. Liver damage by mental stress is worse. If human mind gets rest, damaged liver cells are recovered. The thing is that there is no extra time for rest for modern citizens. So, excessive mental stress, heavy smoke and alcohol drinking make liver damage worse, resulting in mal-function of detoxification, that is mal-function of immune system, which might be a cause of another disease.
  • Liver cirrhosis is caused by fibrosis of liver tissues, which is the condition of losing homeostasis between generation and degeneration of connective tissue. That is, connective tissue is over-accumulated in liver tissues, accompanying necrosis or inflammation. Fibrosis of liver tissues is progressed by the excessive generation of connective tissue resulted from the growth and transfer of hepatic stellate cells (HSCs) transformed in the form of myofibroblasts (Gressner et al., Biochem. Biophys. Res. Commun. 151˜222, 1988). Liver cirrhosis is the final stage of every chronic liver diseases, by which liver loses its general functions rapidly with showing the decrease of hepatic blood flow, the reduction of blood flow in liver, mal-function of metabolizing enzyme, qualitative and quantitative changes in blood protein, variation of bile flux, etc.
  • Hepatotoxicity inducers are exemplified by carbon tetrachloride (CCl4), D-galactosamine, lipopolysaccharide (LPS) and bromobenzene, and in particular, carbon tetrachloride is known to induce hepatotoxicity by inducting lipid peroxidation of liver cells (Recknagel et al., Pharmacol. Rev. 19:145-208, 1967; Alpers et al., Mol. Pharmacol. 4:566-573, 1968; Slater T. F., Biochem. J. 222: 1˜15, 1994). Carbon tetrachloride is a hepatotoxicity inducer that has been used to investigate anti-hepatotoxic activity. Precisely, it has been administered to mice or rats, cultured liver cells and cultured liver tissues to induce hepatotoxicity artificially. Carbon tetrachloride is converted into the highly reactive molecular structure of free radical CCl3 in endoplasmic reticulum by metabolizing enzyme like cytochrome P450, by which it acquires a very strong hepatotoxic effect. Free radical CCl3 oxidizes triglyceride accumulated in liver by alcohol and fatty acid on membrane phospholipid, leading to acidification and oxidation of lipid, followed by lipid peroxidation. As a result, organic peroxide is produced. Through such lipid peroxidation, fat is accumulated in liver, protein synthesis is reduced, glycogen is decomposed, and cytoplasmic enzymes in blood vessel are destroyed, resulting in necrosis of liver tissues (Chang I. M., et al., Drug and chemical toxicology 6, 443-453, 1983) Free radical also harms Golgi apparatus, so that protein release out of cells is affected, suggesting that not only liver but also kidney might be damaged.
  • Anti-oxidation not only inhibits or prevents lipid peroxidation but also has liver protective and anti-inflammatory effects. Thus, an antioxidant compound has been used for the protection of liver and liver cells against attacks by reactive oxygen intermediate.
  • Antioxidant agents separated from natural resources such as flavonoid, quercetin, silymarin or vitamin E have been reported to have positive effect on lipid peroxidation and hepatic fibrosis. And, N-acetylcysteine (NAC) has been confirmed to reduce oxidative stress and hepatic fibrosis in the early stage of hepatic fibrosis by its anti-oxidative activity. Picrorhiza Kurroa (kutkin) is another natural anti-oxidative compound that has liver protective and anti-fibrosis effects by reducing damage caused by lipid peroxidation and free radical.
  • As of today, the treatment methods for liver diseases are largely divided into two ways; one is a dietetic therapy and the other is medicinal therapy. In most cases, the two methods are used together. For medicinal therapy, in variety of medicines having different functions are used according to the cause and type of liver disease. For example, liver cell reproduction stimulator and/or liver function protector such as ursodeoxycholic acid, silymarin (Biotech. Therapeutics, 4, 263-270, 1993), DDB (biphenyl dimethyl dicarboxylate; Biochem. Biophy. Res. Comm., 103, 1131-1137, 1981), glutathione, glycyrrhizin, etc, antiviral agent such as acyclovir, and immunosuppressive drug such as corticosteroid, 6-mercaptopurine (6-MP), azathioprine, etc, are in use. However, liver disease is developed not by just one reason but by co-work of many factors. Thus, one medicine having a certain function is not enough for the treatment of every kinds of liver disease. The conventional medicine for the treatment of liver diseases has problems of unexpected reaction and other side effects by long-term or mass administration.
  • In the meantime, kidney has functions of regulating the concentrations of ion and body fluids, urinating waste products (urea, uric acid, creatinine, etc) and eliminating toxic substances, drugs and metabolites out of the system after counteracting poison. Malonedialdehyde (MDA) and 4-hydroxynonenal (HNE), products from lipid peroxidation in tissues, have been known as indices for cell damage. And, superoxide dismutase catalizing lipid peroxidation has been known to be involved in recovery from cell damage (Slater T F. Biochem. J., 222, 1-15, 1994; Esterbauer H, Schauer R J, Zollner H., 1994; Free Radical Biology & Medicine 11, 81-128, 1992). Besides, alkaline phosphatase (ALP) and blood urea nitrogen (BUN) are also in use as diagnostic indices for kidney functions. In particular, the increase of BUN indicates the decrease of glomerular filtration rate (GFR) by azotemia. Prerenal azotemia means kidney mal-function without kidney damage, which is resulted from hypoperfusion by congestive heart failure, shock, hypovolemia and hemorrhage. On the other hand, postrenal azotemia is caused when the flow of urine is blocked in the lower part of kidney. In the case of postrenal azotemia, full recovery is expected by the elimination of the cause. When azotemia accompanies various clinical symptoms and biochemical disorders, it is called uremia. Thus, uremia is not only a simple biochemical disorder but also a syndrome carrying metabolic disorders, endocrine disorders, gastrointestinal disorders, neuromuscular disorders and cardiovascular disorders, in addition to elimination disorders. Diseases caused by mal-function of kidney are exemplified by acute pyelonephritis, chronic pyelonephritis, renal tuberculosis, UTI, urinary stone, renal cell cancer, etc.
  • Hovenia dulcis Thunb. is a kind of deciduous broad-leaved tall tree belonging to Rhamnaceae, which is also called ‘Jigumok’ in Chinese medicine. There is an explanation on Hovenia dulcis Thunb. in Bon-cho-kang-mok that it tastes sweet and plain, has no toxicity, makes the five viscera (heart, liver, spleen, lungs and kidneys) work smooth and easy, eliminates fever in the chest, quenches thirst, neutralizes alcohol poisoning, relieves vomiting, detoxificates insect poison and might treat five types of hemorrhoids. It has also been known to have liver protective effect. Precisely, it has excellent activities of eliminating halitosis, improving alcoholic hepatitis, fatty liver and liver cirrhosis, anticancer, regulating blood pressure, lowering blood glucose, liver detoxication, and mitigating constipation.
  • Lindera obstiloba is a kind of deciduous broad-leaved tall tree belonging to Lauraceae, which is distributed widely in Korea, Japan, China and Manchuria. The flowers, leaves and stems of Lindera obstiloba emit unique fragrance. The stems of it have been used for medicinal purposes, owing to their anti-bacterial effect. Fresh shoots of it have been used for tea.
  • After long search of natural medicinal compounds having various working mechanisms with low toxicity, the present inventors have completed this invention by confirming that Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof has activities of antioxidative, anti-fibrosis and improving liver functions, in addition to activities of protecting and improving kidney functions.
    • DISCLOSURE Technical Solution
  • It is an object of the present invention to provide a composition comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof as an effective ingredient.
    • BEST MODE
  • The present invention provides a compound comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof as an effective ingredient.
  • The composition of the present invention includes an anti-oxidative composition, an anti-fibrosis composition, a liver function improving composition and a kidney function improving composition.
  • Hereinafter, the present invention is described in detail.
  • The extracting method for Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention is as follows.
  • Hovenia dulcis Thunb or Lindera obstiloba is washed with water and then dried in the shadow. The dried Hovenia dulcis Thunb or Lindera obstiloba is put in a reflex extractor, to which purified water is added and heated at 10° C. for 90 minutes, leading to hot water extraction. The hot water extract is filtered with a filter paper under reduced pressure when it is still hot. The filtrate is concentrated by using a vacuum evaporator. For long-term storage, the solution is dried by using a freeze dryer. The stems, flowers, leaves and seeds of Hovenia dulcis Thunb or Lindera obstiloba are all available in the present invention.
  • The composition rate of herbs for the composition of the present invention is determined based on the dry weight of each herb. Precisely, Hovenia dulcis Thunb and Lindera obstiloba are mixed at the ratio of 3:2˜1:1, and more preferably mixed at the ratio of 2:1˜1:1. Such ratio is determined under the consideration of effective dosage of each herb and side effects of it, and the pharmaceutical effects are dropped rapidly or side effects might be a problem when the ratio is out of the above range.
  • GOT, GPT, ALP, BUN and total bilirubin, which are all liver function indices, are all lowered in the group administered with Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof, indicating that the extract of the present invention has excellent liver function improving effect. In the meantime, ALP and BUN are not only used as liver function indices but also used as kidney function indices. Thus, the lowered levels of ALP and BUN indicate that Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention has excellent kidney function improving effect, as well.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention reduces the amount of hydroxyproline in liver tissues but increases that in kidney tissues, indicating that the extract of the invention has excellent anti-fibrosis and kidney protective effects. In particular, the herbal extract extracted from the mixture of Hovenia dulcis Thunb and Lindera obstiloba shows higher effects than each individual extract, that is the mixture extract reduces hydroxyproline in liver tissues more but increases it in kidney tissues more than each individual extract.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention can reduce the level of malondialdehyde, an index for lipid peroxidation in liver and kidney tissues, indicating that the extract of the invention has excellent anti-oxidative effect.
  • Liver cell line and kidney cell line treated with Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention show high cell viability, indicating that the extract of the present invention has excellent liver cell and kidney cell protective effects.
  • Therefore, the composition of the present invention can be effectively used for the improvement and the protection of liver and kidney functions and for anti-oxidation and anti-fibrosis as well.
  • The composition of the present invention can additionally include, in addition to Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof, one or more effective ingredients having the same or similar functions to the extract of the present invention.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention can be administered orally or parenterally and be used in general forms of pharmaceutical formulation. The herbal mixture extract of the present invention can be prepared for oral or parenteral administration by mixing with generally used fillers, extenders, binders, wetting agents, disintegrating agents, diluents such as surfactant, or excipients. Solid formulations for oral administration are tablets, pills, dusting powders, granules and capsules. These solid formulations are prepared by mixing one or more suitable excipients such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. Except for the simple excipients, lubricants, for example magnesium stearate, talc, etc, can be used. Liquid formulations for oral administration are suspensions, solutions, emulsions and syrups, and the above-mentioned formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives in addition to generally used simple diluents such as water and liquid paraffin. Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions, emulsions, freeze-drying agent and suppositories. Water insoluble excipients and suspensions can contain, in addition to the active compound or compounds, propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc. Suppositories can contain, in addition to the active compound or compounds, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin, etc.
  • The dosage units can contain, for example, 1, 2, 3 or 4 individual doses or ½, ⅓ or ¼ of an individual dose. An individual dose preferably contains the amount of active compound which is administered in one application and which usually corresponds to a whole, ½, ⅓ or ¼ of a daily dose. The effective dosage of Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention is 200˜600 mg/kg, respectively, and more preferably 300˜400 mg/kg, and the administration times are 1˜6 times a day.
  • The composition of the present invention can be administered singly or combination with surgical operation, radiotherapy, hormone therapy, chemotherapy and biological reaction regulator, to improve liver and kidney functions and to obtain anti-oxidative and anti-fibrosis effects.
  • The composition of the present invention can be added in health food to improve liver and kidney functions and to obtain anti-oxidative and anti-fibrosis effects. At this time, Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention can be added as it is or after being mixed with other food or ingredients, according to the conventional method. The mixing ratio of effective ingredients is determined by the purpose of use (prevention, health or therapeutic treatment). In the case of producing food or beverages containing Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention, the extract is preferably added by under 15 weight %, more preferably under 10 weight %, to the raw material. However, the content of the extract might be less than the above when it is administered for long-term to improve health conditions but the effective dosage could contain more than the above amount because the extract of the invention is very safe.
  • There is no limit in applicable food, which is exemplified by meats, sausages, bread, chocolate, candies, snacks, cookies, pizza, ramyun, noodles, gums, dairy products including ice cream, soups, beverages, tea, drinks, alcoholic drinks and vitamin complex, etc, and in fact every health food generally produced are all included.
  • Health beverages comprising the composition of the present invention can additionally include various flavors or natural carbohydrates, etc, like other beverages. The natural carbohydrates above can be one of monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xilytole, sorbitol and erythritol. As a sweetener, either natural sweetener such as thaumatin and stevia extract or artificial sweetener such as saccharin and aspartame can be used. The ratio of natural carbohydrate to the composition of the present invention is preferably 0.01˜0.04 g to 100 ml, more preferably 0.02˜0.03 g to 100 ml.
  • In addition to the ingredients mentioned above, the composition of the present invention can include in variety of nutrients, vitamines, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, arginic acid and its salts, organic acid, protective colloidal viscosifiers, pH regulators, stabilizers, antiseptics, glycerin, alcohols, carbonators which used to be added to soda, etc. The composition of the present invention can also include natural fruit juice, fruit beverages and/or fruit flesh addable to vegetable beverages. All the mentioned ingredients can be added singly or together. The mixing ratio of those ingredients does not matter in fact, but in general, each can be added by 0.01˜0.1 weight part per 100 weight part of the composition of the invention.
    • MODE FOR INVENTION
  • Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.
  • However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.
    • Example 1 Preparation of Hovenia dulcis Thunb Extract
  • Hovenia dulcis Thunb was washed with water and then dried in the shadow. 20 g of the dried Hovenia dulcis Thunb was put in a reflex extractor, to which 1.5 l of purified water was added and was heated at 100° C. for 90 minutes. The hot water extract was filtered with a filter paper under the reduced pressure when it was still hot. The filtrate was concentrated by using a vacuum evaporator. It was dried by a freeze dryer for long-term storage.
  • The concentrated solution was used for animal test (2 ml/rat/day).
    • Example 2 Preparation of Lindera obstiloba Extract
  • By using Lindera obstiloba, Lindera obstiloba extract was prepared in analogy to the procedure as described above in example 1.
  • The concentrated solution was used for animal test (2 ml/rat/day).
    • Example 3 Preparation of Herbal Mixture Extract
  • 20 g of dried Hovenia dulcis Thunb and 10 g of dried Lindera obstiloba stem were mixed and the extract thereof was prepared in analogy to the procedure as described in example 1.
  • The concentrated solution was used for animal test (2 ml/rat/day), and 4-fold concentrated solution was used for MTT and NR assay (50 μl/well).
    • Experimental Example 1 Anti-Oxidative, Anti-Fibrosis, Liver and Kidney Function Improving and Protective Effects of the Extract in Rats Having Liver and Kidney Damage Induced by Long-Term Administration of Carbon Tetrachloride
  • Experiments were performed as follows in order to investigate anti-oxidative and anti-fibrosis effects as well as liver and kidney function improving and protective effects of Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention in liver and kidney damage models.
  • 1. Test Animal
  • 12 week old Sprague-Dawley rats weighing about 180˜210 g (Damul science, Osan, Korea) were used as test animals. Breeding temperature was 23±2° C. and relative humidity was maintained as 60±10%. Feed (Purina feed) and water were freely given, and day-night cycle was regulated.
  • The animals were adapted to the test room for 2 weeks, and then divided into 5 groups; {circle around (1)} normal group, {circle around (2)} CCl4 treating group, {circle around (3)} CCl4+herbal mixture extract treating group, {circle around (4)} CCl4 +Hovenia dulcis Thunb extract treating group and {circle around (5)} CCl4 +Lindera obstiloba extract treating group. Each group was composed of 10 rats.
  • 2. Inducement of Liver Fibrosis (Cirrhosis) and Kidney Damage
  • Experimental groups, except the normal group, were administered with olive oil and CCl4 mixture by 1 ml/rat/day, three times a week for 4 weeks so as to induce liver fibrosis (cirrhosis) and kidney damage.
  • CCl4 treating group was administered orally with distilled water by 2 ml/rat/day, CCl4+herbal mixture extract treating group was administered orally with the herbal mixture extract prepared in the above example 3 by 2 ml/rat/day, CCl4 +Hovenia dulcis Thunb extract treating group was administered orally with Hovenia dulcis Thunb extract prepared in the above example 1 by 2 ml/rat/day and CCl4 +Lindera obstiloba extract treating group was administered orally with Lindera obstiloba extract prepared in the above example 2 also by 2 ml/rat/day.
  • Rats in every group including the normal group were weighed, and then anesthetized by ether. Blood was taken from heart by heart puncture, which was left at room temperature for over 2 hours. Then, centrifugation was performed at 3000 rpm for 10 minutes to obtain serum, which was stored at −20° C. The serum was examined to measure the level of GOT, GPT, alkaline phosphatase, BUN and total bilirubin.
  • Liver and kidney of a rat, which were already damaged by artificial inducement, were extracted and washed with phosphate buffer (pH 7.0), followed by measuring the weight. A part of liver and kidney tissues were kept at −75° C. for the use of measuring hydroxyproline and malondialdehyde (MDA).
  • Weight changes were measured every week. Ears, tail and feet were investigated to detect the sign of jaundice. The liver was weighed as the rat was sacrificed.
  • The results were presented by mean±SD, and the significance of difference in averages between control group and experimental group was examined by student's t-test. It was judged as statistically significant when p<0.005.
  • The results are shown in Table 1.
    TABLE 1
    Liver tissue Kidney tissue
    (Liver (Kidney
    weight/ weight/
    Liver body kidney body
    Weight weight weight) × 100 weight weight) × 100
    (g) (g) (%) (g) (%)
    Normal group 200.8 ± 8.6   6.3 ± 0.3 3.2 ± 1.3 1.23 ± 0.09 0.64 ± 0.03
    CCl4 treating 167.3 ± 19.4 12.9 ± 1.9 7.7 ± 0.7 2.18 ± 0.16 0.97 ± 0.17
    group
    CCl4 + herbal 190.7 ± 10.3 11.7 ± 1.6* 6.7 ± 0.8* 1.63 ± 0.10 0.86 ± 0.05*
    mixture
    extract
    treating group
    CCl4 + Hovenia 173.2 ± 17.3 13.4 ± 1.6 7.0 ± 0.6 1.57 ± 0.09 0.91 ± 0.2*
    dulcis
    Thunb extract
    treating group
    CCl4 + Lindera 181.8 ± 16.1 12.5 ± 1.2 6.9 ± 0.5* 1.59 ± 0.11 0.88 ± 0.07
    obstiloba
    extract
    treating group

    *p < 0.005
  • As shown in Table 1, the changes of the ratio of body weight to liver weight in experimental groups treated with Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention were not significant, comparing to a control. Likewise, the changes of the ratio of body weight to kidney weight were also insignificant, comparing to a control.
  • 3. Serological and Biochemical Test
  • 1) GOT(AST) Measurement (Using EMBIEL Kit)
  • 500 μl of AST substrate solution was put in two falcon tubes, which were heated at 37° C. for 3˜5 minutes. The substrate solution was diluted with standard solution in one tube, and in the other tube, 100 μl of serum sample was added. Reaction was induced in both tubes at 37° C. for 60 minutes. 100 μl of purified water and 500 μl of coloring solution (2,3-dinitrophenylhydrazine) were added to each tube, which were then left at room temperature for 20 minutes. 5 ml of 0.4 N NaOH was added to each tube, followed by reaction at room temperature for 10 minutes. OD was measured at 505 nm.
  • 2) GPT(ALT) Measurement (Using EMBIEL Kit)
  • 150 μl of ALT substrate solution was put in two falcon tubes, which were heated at 37° C. for 4 minutes. The substrate solution was diluted with standard solution in one tube, and in the other tube, 100 μl of serum sample was added and reaction was induced at 37° C. for 30 minutes in both tubes. 100 μl of purified water and 500 μl of coloring solution (2,3-dinitrophenylhydrazine) were added to each tube, which was left at room temperature for 20 minutes. 1.5 ml of 0.4 N NaOH was added to each test tube, followed by reaction at room temperature for 10 minutes. OD was measured at 505 nm.
  • 3) ALP (Alkaline Phosphatase) Measurement
  • 2.0 ml of ALP substrate buffer (sodium-2-phenylphosphate) was put in three test tubes, which were reacted at 37° C. for 3˜5 minutes. 50 μl of serum sample, 50 μl of purified water and 50 μl of standard solution were added to test tubes respectively, followed by reaction at 37° C. for 15 minutes. 2.0 ml of coloring reagent was added to each test tube and then left at room temperature for 10 minutes. OD was measured at 570 nm within 60 minutes.
  • 4) BUN (Blood Urea Nitrogen) Measurement
  • 20 μl of serum sample, 20 μl of purified water and 20 μl of standard solution were put in three test tubes respectively. 2.0 ml of enzyme solution was added thereto, followed by reaction at 37° C. for 5 minutes. 2.0 ml of coloring reagent was added to each tube, which was heated at 37° C. for 10 minutes. OD was measured at 580 nm within 60 minutes.
  • 5) Measurement of Total Bilirubin
  • 100 μl of serum sample, 100 μl of purified water and 100 μl of standard solution were put in three test tubes respectively, to which coloring reagent working toward total bilirubin was added by 600 μl per tube. 600 μl of diazo mixture was added to each test tube, which was left at room temperature for 10 minutes. 600 μl of ferring reagent was added to each tube to induce reaction. OD was measured at 600 nm within 2 hours.
  • The results are shown in Table 2.
    TABLE 2
    Total
    BUN bilirubin
    GOT(IU) GPT(IU) ALP(KA) (mg/dl) (mg/dl)
    Normal group 61.78 ± 6.0  13.2 ± 1.0  63.5 ± 11.2  13.6 ± 1.1  0.2 ± 0.05
    CCl4 treating 241.8 ± 43.1 145.3 ± 38.1 156.9 ± 36.1  23.4 ± 2.1  1.6 ± 0.92
    group
    CCl4 + Herbal 137.6 ± 52.4**  69.6 ± 47.0* 137.0 ± 26.0 18.04 ± 6.91 0.27 ± 0.14
    mixture
    extract
    treating group
    CCl4 + Hovenia 165.1 ± 46.4**  70.9 ± 42.2* 143.1 ± 37.9  18.6 ± 2.1*  0.7 ± 0.04
    dulcis
    Thunb extract
    treating group
    CCl4 + Lindera 144.5 ± 5.7**  74.4 ± 17.6* 138.2 ± 14.8  18.4 ± 3.6 —
    obstiloba
    extract
    treating group

    *p < 0.05,

    **p < 0.005
  • As shown in Table 2, the levels of GOT, GPT, ALP, BUN and total bilirubin, which are liver function indices, were significantly low in experimental groups treated with Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention respectively, comparing to a control. In particular, the level of those indices in the group treated with herbal mixture extract was the lowest.
  • Thus, Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention were proved to have excellent liver function improving effect.
  • And, ALP and BUN are the indices not only for the liver function but also for the kidney function, so that the lowered levels of ALP and BUN by the extract of the invention also mean that Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention have excellent kidney function improving effect as well.
  • 4. Measurement of Hydroxyproline (Hyp)
  • 1) Preparation of Reagents
  • {circle around (1)} Acetate Citrate Buffer
  • 50 g of sodium acetate trihydrate, 37.5 g of trisodium citrate and 5.5 g of citric acid monohydrate were mixed in 395 ml of isopropanol. And, the total volume of the mixture was adjusted to 1 l by adding distilled water. pH of the mixing solution was also adjusted to 6.0. The final solution was stored at 4° C.
  • {circle around (2)} Chloramine-T Solution
  • 84 mg of chloramine-T was dissolved in 10 ml of acetate citrate buffer.
  • {circle around (3)} Ehrilich's Reagents
  • 10 g of p-dimethylaminobenzaldehyde and 11 ml of 60% perchloric acid were mixed to prepare a storage solution. 3 ml of the storage solution was mixed with 8.0 ml of isopropanol, resulting in Ehrilich's reagent. The reagent was prepared right before use, and the storage solution was stored at 4° C. in shading.
  • 2) Measurement of Hydroxyproline
  • 0.2 g of liver (or kidney) tissues which were frozen or freeze-dried (−50° C., 72 hours) were distributed in a 10 ml glass bottle. 4 ml of 6 N HCl was put in the bottle, followed by homogenization with a homogenizer. Then, hydrolysis was performed in a dry oven at 110° C. for 10˜24 hours, followed by filtering with a Whatmann filter paper. Likewise, standard solution which was diluted with trans-hydroxyproline 6 N HCl at different concentrations of 0, 0.2, 0.4, 0.6, 0.8 and 1.0 μg/50 μl was also hydrolyzed at 110° C. for 12˜14 hours. Each sample and standard solution were taken by 50 μl each and completely dried in a glass bottle to eliminate HCl. 1.2 ml of 50% isopropanol was added to dissolve sediments. 200 μl of chloramine-T solution was added thereto, followed by reaction at room temperature for 10 minutes. Then, 1.2 ml of Ehrilich's reagent was added. Coloring was induced at 50° C. for 90 minutes, followed by cooling down at room temperature. OD was measured at 558 nm by using a spectrophotometer.
  • The content of hydroxyproline in liver tissues (or kidney tissues) was measured by the below formula.
    C[Hydroxyprolone concentration of 0.2 g liver tissue (or kidney tissue)]=[HA(OD of sample)/SA(OD of standard solution diluted with 1.0 μg/50 μl trans-hydroxyproline 6 N HCl)]×80
    C×5=Hydroxyproline amount/g liver tissue (or kidney tissue)
  • The results are shown in Table 3.
    TABLE 3
    Hydroxyproline amount (μg/g)
    Liver tissue Kidney tissue
    Normal group 997.7 ± 87.8 918.2 ± 78.7
    CCl4 treating group 2201.6 ± 16.0  825.6 ± 57.6
    CCl4 + Herbal 1094.3 ± 186.7 870.4 ± 74.3
    mixture
    extract treating
    group
    CCl4 + Hovenia *5341118.3 ± 255.0*   850.2 ± 57.6
    dulcis Thunb
    extract treating
    group
    CCl4 + Lindera  1110.1 ± 201.0* 860.4 ± 69.3
    obstiloba
    extract treating
    group

    *p < 0.005
  • As shown in Table 3, in the case of experimental groups each treated with Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention, the content of hydroxyproline was lower in liver tissues and higher in kidney tissues, comparing to a control. In particular, in the case of herbal mixture extract treating group, the content of hydroxyproline in liver tissues was significantly low (50.8%), comparing to a control. But the content of hydroxyproline in kidney was 5.5% higher than a control, 3.0% higher than the group treated with Hovenia dulcis Thunb extract, and 1.2% higher than the group treated with Lindera obstiloba extract.
  • Thus, Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention were confirmed to have excellent anti-fibrosis and kidney protective effects.
  • 5. Measurement of MDA (Malondialdehyde)
  • Homogenized tissue sample [0.2 g of liver tissues (or kidney tissues) in 1.8 ml of 1.15% KCl] and 200 μl of diluted standard material (0, 4, 8, 16, 32 nmol/200 μl tetramethoxypropane) were put together in falcon tube. 200 μl of standard solution diluted with sample was mixed with 100 μl of 0.2% SDS, followed by reaction at room temperature for 10 minutes. 750 μl of 20% acetic acid and 750 μl of 0.8% thiobarbiturate were added thereto. The solution was reacted at 95° C. for 30 minutes, then cooled down in ice. Upon completion of cooling down, 2 ml of n-butanol was added, followed by centrifugation to obtain supernatant. OD of the supernatant was measured at 532 nm by a spectrophotometer.
  • The contents of MDA in serum and in tissues were measured as follows.
    C[Malondialdehyde concentration of 0.2 g of liver tissue (or kidney tissue)(or 200 μl of serum)]=[HA(OD of sample)/SA(OD of standard solution (8 μmol/1.15% KCl 200 μl))×80
    C×5=Malondialdehyde amount (μmol/ml)
  • The results were shown in Table 4.
    TABLE 4
    Malondialdehyde amount (μmol/ml)
    Liver tissue Kidney tissue
    Normal group 89.6 ± 3.7 142.3 ± 12.7
    CCl4 treating group 151.3 ± 27.7 181.4 ± 24.4
    CCl4 + Herbal  105.9 ± 12.9* 161.7 ± 13.2
    mixture extract
    treating group
    CCl4 + Hovenia 130.7 ± 25.9 168.3 ± 19.8
    dulcis Thunb
    extract treating group
    CCl4 + Lindera *593121.3 ± 17.6    156.6 ± 14.7*
    obstiloba
    extract treating group

    *p < 0.05
  • As shown in Table 4, in experimental groups each treated with Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention, the amount of malondialdehyde, an index for lipid peroxidation, was low in liver and kidney tissues, comparing to a control. In particular, in the group treated with herbal mixture extract, the content in liver tissues was significantly low (31.0%) and that in kidney tissues was also very low (13.0%), comparing to a control.
  • Therefore, Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention were confirmed to have excellent anti-oxidative and kidney protective effects.
    • Experimental Example 2 Cytotoxicity Test
  • The cell lines used in this invention were NCTC clone 1469 (liver cell line) and vero (kidney cell line), which were purchased from Korea Cell Line Bank (KCLB).
  • 5 mg of MTT powder was dissolved in 1 ml of phosphate buffer, which was stirred well and then filtered by 0.4 μm filter, resulting in MTT storage solution.
  • 4 mg of NR powder was dissolved in 1 ml of tertially distilled water, which was then stirred well and filtered by 0.4 μm filter, resulting in NR storage solution.
  • Trypsin-EDTA containing 0.5% trypsin and 5.3 mM EDTA was purchased and 10-fold diluted with PBS before use.
    • 1) MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] Assay
  • After removing medium, 1 ml of trypsin-EDTA solution was added, which was left for 10˜20 minutes. Cells were isolated from the vessel and then transferred to 15 ml falcon tube. 1 ml of medium was added to culture flask and shacked to isolate all the remaining cells, which were also put in the falcon tube. 10 μl of cell suspension was put in hemocytometer and then cells were counted (2.5×104 cell/ml). Cells were inoculated to 96 well plate by 50 μl (1˜2×105 cells)/well, to which 150 μl of medium (DMEM+10% FBS+antibiotics) was added. The cells were cultured in a 37° C., 5% CO2 incubator for 24 hours, resulting in cell adhesion.
  • 24 hours later, medium was carefully removed from the cells adhered onto the 96 well plate (Careful attention is required for the medium not to be stained with cells and contaminated). 150 μl of medium was supplemented with 50 μl of Hovenia dulcis Thunb extract prepared in example 1, 50 μl of Lindera obstiloba extract prepared in example 2 and 50 μl of herbal mixture extract prepared in example 3, making total volume 200 μl. The solution was cultured in a 37° C., 5% CO2 incubator for 24 hours. At this time, the extract should be added later, otherwise cells are damaged. So, medium should be added first and then the extract was put therein. Upon culturing, the 96 well plate was taken to remove medium. 50 μl/ml of MTT dye (50 μl of storage solution+950 μl of medium) was added to dilute the solution, which was distributed in each well by 50 μl, followed by further culture in a CO2 incubator for 4 hours. After eliminating supernatant, 100 μl of DMSO was added, followed by stirring for 10 minutes. OD was measured at 540 nm with ELISA reader.
  • Only medium was added to a control, and viability was investigated.
    • 2) NR (Neutral Red: 3-amino-7-dimethylamino-2-methyl phenazine) Assay
  • After removing medium, 1 ml of trypsin-EDTA solution was added, which was left for 10˜20 minutes. Cells were isolated from the vessel and then transferred to 15 ml falcon tube. 1 ml of medium was added to culture flask and shaked to isolate all the remaining cells, which were also put in the falcon tube. 10 μl of cell suspension was put in hemocytometer and then cells were counted (2.5×104 cell/ml). Cells were inoculated to 96 well plate by 50 μl (1˜2×105 cells)/well, to which 150 μl of medium (DMEM+10% FBS+antibiotics) was added. The cells were cultured in a 37° C., 5% CO2 incubator for 24 hours, resulting in cell adhesion.
  • 24 hours later, medium was carefully removed from the cells adhered onto the 96 well plate (Careful attention is required for the medium not to be stained with cells and contaminated). 150 μl of medium was supplemented with 50 μl of Hovenia dulcis Thunb extract prepared in example 1, 50 μl of Lindera obstiloba extract prepared in example 2 and 50 μl of herbal mixture extract prepared in example 3, making total volume 200 μl. The solution was cultured in a 37° C., 5% CO2 incubator for 24 hours. At this time, the extract should be added later, otherwise cells are damaged. So, medium should be added first and then the extract was put therein.
  • Upon culturing, the 96 well plate was taken to remove medium. 10 μl/ml of NR dye (10 μl of storage solution+990 μl of medium) was added to dilute the solution, which was distributed in each well by 200 μl, followed by further culture in a 37° C., 5% CO2 incubator for 3 hours. After eliminating the medium, the plate was washed with 100 μl of 1% CaCl2 and 0.5% formaldehyde. Supernatant was removed. Then, 200 μl of 1% acetic acid and 50% ethanol was added, followed by stirring for 10 minutes. OD was measured at 540 nm with ELISA reader.
  • Only medium was added to a control, and viability was investigated.
  • The results were shown in Table 5.
    TABLE 5
    Liver cell line Kidney cell line
    (NCTC) (Vero)
    MTT(%) NR(%) MTT(%) NR(%)
    Herbal 105.70 ± 12.9 109.00 ± 5.3 96.20 ± 4 106.90 ± 7.4
    mixture
    extract
    (Hovenia
    dulcis
    Thunb +
    Lindera
    obstiloba)
    Hovenia 44.60 ± 6.6  42.30 ± 4.1 98.40 ± 4.1  99.00 ± 12
    dulcis Thunb
    extract
    Lindera  95.7 ± 10.9  96.7 ± 5.7  98.7 ± 3.8  97.3 ± 3.5
    obstiloba
    extract
  • As shown in Table 5, Lindera obstiloba extract and herbal mixture extract of the present invention showed high cell viability in liver cell line. In particular, herbal mixture extract is more effective to increase cell viability in liver cell line than Hovenia dulcis Thunb extract. In the meantime, Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention did not harm cell viability in kidney cell line.
  • Therefore, Hovenia dulcis Thunb extract, Lindera obstiloba extract and herbal mixture extract thereof of the present invention were confirmed to have excellent liver and kidney protective effects.
  • Preparative examples of the composition of the present invention are described hereinafter.
  • Pharmaceutical compositions comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention were prepared as follows.
    • Preparative Example 1 Preparation of Pharmaceutical Compositions
  • 1. Preparation of Powders
  • Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) 2g
  • Lactose 1 g
  • The above-mentioned ingredients were mixed together, and airtight bag was filled with the mixture to prepare powders.
  • 2. Preparation of Tablets
    Hovenia dulcis Thunb extract (or Lindera obstiloba 100 mg
    extract or herbal mixture extract thereof)
    Corn starch 100 mg
    Lactose 100 mg
    Magnesium stearate  2 mg
  • The above-mentioned ingredients were mixed together, and tablets were prepared by tabletting according to the conventional tablet producing method.
  • 3. Preparation of Capsules
    Hovenia dulcis Thunb extract (or Lindera obstiloba 100 mg
    extract or herbal mixture extract thereof)
    Corn starch 100 mg
    Lactose 100 mg
    Magnesium stearate  2 mg
  • The above-mentioned ingredients were mixed together, and gelatin capsules were filled with the mixture to prepare capsules according to the conventional capsule producing method.
    • Preparative Example 2 Preparation of Food
  • Food comprising Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention was prepared as follows.
  • 1. Preparation of Spices and Condiments
  • Spices and condiments for health improvement that contains Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention by 20˜95 weight % were prepared.
  • 2. Preparation of Tomato Ketchup and Source
  • Tomato ketchup or source for health improvement was prepared by adding Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention by 0.2˜1.0 weight % to tomato ketchup or source.
  • 3. Preparation of Flour Foods
  • Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention was added to flour by 0.5˜5.0 weight %, and the mixture was used to prepare bread, cake, cookies, cracker and noodles to produce health improving foods.
  • 4. Preparation of Soups and Gravies
  • Health improving processed meat, noodle soups and gravies were prepared by adding Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention by 0.1˜5.0 weight % to soups and gravies.
  • 5. Preparation of Ground Beef
  • Health improving ground beef was prepared by adding Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention by 10 weight % to ground beef.
  • 6. Preparation of Dairy Products
  • Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention was added to milk by 5˜10 weight %, which was then used for the production of health improving dairy products including butter and ice cream.
  • 7. Preparation of Cerial
  • Brown rice, barley, glutinous rice and Job's tears were gelatinized, dried and roasted by the conventional method, followed by pulverization with a pulverizer, resulting in 60-mesh granules.
  • Black bean, black sesame, Perilla japonica were steamed, dried and roasted by the conventional method, followed by pulverization with a pulverizer, resulting in 60-mesh granules.
  • Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention was concentrated under reduced pressure in a vacuum concentrator, and then dried by spray dryer. The dried product was pulverized into 60-mesh granules.
  • Crops, seeds and the dried powder of Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) were mixed by the following ratio.
  • Crops (brown rice 30 weight %, job's tears 15 weight %, barley 20 weight %),
  • Seeds (Perilla japonica 7 weight %, black bean 8 weight %, black sesame 7 weight %),
  • Dried powder of Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) (3 weight %),
  • Ganoderma lucidum (0.5 weight %),
  • Rehmannia glutinosa (0.5 weight %)
    • Preparative Example 3 Preparation of Beverages
  • 1. Preparation of Carbonated Beverage
  • Sugar (5˜10%), citric acid (0.05˜0.3%), caramel (0.005˜0.02%) and vitamin C (0.1˜1%) were mixed together, to which purified water (79˜94%) was added, resulting in syrup. The syrup was sterilized at 85˜98° C. for 20˜180 seconds, then mixed with cooling water at the ratio of 1:4. Carbon dioxide was injected by 0.5˜0.82% thereto, resulting in the preparation of carbonated beverage comprising Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention.
  • 2. Preparation of Health Beverage
  • Optional ingredients such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%) and Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) were mixed evenly. After pasteurization, the mixture was put in small container such as pet or glass bottle, resulting in the preparation of health beverages.
  • 3. Preparation of Vegetable Juice
  • 5 g of Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention was added to 1,000 ml of tomato or carrot juice to prepare health improving vegetable juice.
  • 4. Preparation of Fruit Juice
  • 1 g of Hovenia dulcis Thunb extract (or Lindera obstiloba extract or herbal mixture extract thereof) of the present invention was added to 1,000 ml of apple or grape juice to prepare health improving fruit juice.
    • INDUSTRIAL APPLICABILITY
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention is highly effective for the improvement of liver functions since it can lower the level of GOT, GPT, ALP, BUN and total bilirubin, which are major liver function indices. ALP and BUN are also used as kidney function indices, so the decrease of the level of ALP and BUN by the extract of the present invention indicates that Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the invention can improve kidney functions as well.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention also can lower the amount of hydroxyproline in liver but increase the amount of hydroxyproline in kidney, suggesting that the extract above has excellent anti-fibrosis and kidney protecting effects.
  • In addition, Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention can lower the level of malondialdehyde, an index of lipid peroxidation in liver and kidney tissues, suggesting that the extract has excellent anti-oxidative effect.
  • Hovenia dulcis Thunb extract, Lindera obstiloba extract or herbal mixture extract thereof of the present invention promotes cell viability in liver and kidney cell lines, indicating that the extract has excellent liver and kidney cell protective effects.
  • Therefore, the composition of the present invention can be effectively used not only for anti-oxidation and anti-fibrosis but also for the protection and the improvement of liver and kidney functions.

Claims (16)

1. An anti-oxidative composition comprising Hovenia dulcis Thunb extract as an effective ingredient.
2. An anti-oxidative composition comprising Lindera obtusiloba extract as an effective ingredient.
3. An anti-oxidative composition comprising herbal mixture extract of Hovenia dulcis Thunb and Lindera obtusiloba as an effective ingredient.
4. The anti-oxidative composition as set forth in claim 3, wherein the Hovenia dulcis Thunb extract and Lindera obtusiloba extract are mixed at the ratio of 2:1˜1:1.
5. An anti-fibrosis composition comprising Hovenia dulcis Thunb extract as an effective ingredient.
6. An anti-fibrosis composition comprising Lindera obtusiloba extract as an effective ingredient.
7. An anti-fibrosis composition comprising herbal mixture extract of Hovenia dulcis Thunb and Lindera obtusiloba as an effective ingredient.
8. The anti-fibrosis composition as set forth in claim 7, wherein the Hovenia dulcis Thunb extract and Lindera obtusiloba extract are mixed at the ratio of 2:1˜1:1.
9. A liver function improving composition comprising Hovenia dulcis Thunb extract as an effective ingredient.
10. A liver function improving composition comprising Lindera obtusiloba extract as an effective ingredient.
11. A liver function improving composition comprising herbal mixture extract of Hovenia dulcis Thunb and Lindera obtusiloba as an effective ingredient.
12. The liver function improving composition as set forth in claim 11, wherein the Hovenia dulcis Thunb extract and Lindera obtusiloba extract are mixed at the ratio of 2:1˜1:1.
13. A kidney function improving composition comprising Hovenia dulcis Thunb extract as an effective ingredient.
14. A kidney function improving composition comprising Lindera obtusiloba extract as an effective ingredient.
15. A kidney function improving composition comprising herbal mixture extract of Hovenia dulcis Thunb and Lindera obtusiloba as an effective ingredient.
16. The kidney function improving composition as set forth in claim 15, wherein the Hovenia dulcis Thunb extract and Lindera obtusiloba extract are mixed at the ratio of 2:1˜1:1.
US10/587,286 2004-01-31 2005-01-31 Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof Abandoned US20070160699A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/465,830 US7846484B2 (en) 2004-01-31 2009-05-14 Composition comprising Hovenia dulcis thunb. extract, Lindera obtusiloba blume extract, or herbal mixture extract thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR10-2004-0006435A KR100536856B1 (en) 2004-01-31 2004-01-31 Composition comprising herbal mixture extract
KR1020040006437A KR100586269B1 (en) 2004-01-31 2004-01-31 Composition containing ginger tree extract as an active ingredient
KR10-2004-0006435 2004-01-31
KR10-2004-0006436A KR100536855B1 (en) 2004-01-31 2004-01-31 Composition comprising Hovenia dulcis Thunb. extract for improvement of kidney function
KR10-2004-0006437 2004-01-31
KR10-2004-0006436 2004-01-31
PCT/KR2005/000283 WO2005072758A1 (en) 2004-01-31 2005-01-31 Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/000283 A-371-Of-International WO2005072758A1 (en) 2004-01-31 2005-01-31 Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/465,830 Continuation US7846484B2 (en) 2004-01-31 2009-05-14 Composition comprising Hovenia dulcis thunb. extract, Lindera obtusiloba blume extract, or herbal mixture extract thereof

Publications (1)

Publication Number Publication Date
US20070160699A1 true US20070160699A1 (en) 2007-07-12

Family

ID=34831001

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/587,286 Abandoned US20070160699A1 (en) 2004-01-31 2005-01-31 Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof
US12/465,830 Expired - Fee Related US7846484B2 (en) 2004-01-31 2009-05-14 Composition comprising Hovenia dulcis thunb. extract, Lindera obtusiloba blume extract, or herbal mixture extract thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/465,830 Expired - Fee Related US7846484B2 (en) 2004-01-31 2009-05-14 Composition comprising Hovenia dulcis thunb. extract, Lindera obtusiloba blume extract, or herbal mixture extract thereof

Country Status (4)

Country Link
US (2) US20070160699A1 (en)
EP (1) EP1718167A4 (en)
JP (1) JP2007519715A (en)
WO (1) WO2005072758A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009091120A2 (en) 2008-01-18 2009-07-23 Yang Ji Chemical Co., Ltd. Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
CN102665747A (en) * 2009-11-20 2012-09-12 杨智化学（株） Composition for Improving Blood Circulation Containing Santia Cinnamon Extract as Active Ingredient
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20210402323A1 (en) * 2020-06-30 2021-12-30 Henan Zhongda Hengyuan Biotechnology Stock Co., Ltd. Method of preparing hovenia dulcis thunb extract rich in dihydromyricetin

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082785A2 (en) * 2009-01-16 2010-07-22 한올제약주식회사 Oral pharmaceutical composition
KR101040682B1 (en) * 2010-11-04 2011-06-10 김병주 Method for producing a composition with enhanced immunity and composition according thereto
CN103222995B (en) * 2013-05-15 2014-09-03 李伟权 Application of gynura divaricata in preparing liver-protecting drug or health-care food

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037999A (en) * 1983-08-09 1985-02-27 Osaka Chem Lab Simple method for testing drug effective to hepatopathy
US5545423A (en) * 1991-11-25 1996-08-13 Vivorx, Inc. Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
KR100214801B1 (en) * 1996-10-05 1999-08-02 신국현 Antibiotics isolated from ginger
KR100403721B1 (en) * 2001-01-31 2003-11-05 (주)생명의나무 Lower alcohol insoluble extract and a polysaccharide therein isolated from hovenia dulcis var. koreana nakai having antihepatotoxic and anti-hangover activity and composition containing same
KR100439012B1 (en) * 2001-03-29 2004-07-03 박근형 Antioxidants comprising extracts from the leaves and stems of hovenia dulcis thunb and process for separating extracts thereof
WO2002091845A1 (en) * 2001-05-17 2002-11-21 Korea Confidence Co., Ltd Lingering intoxication aquaous tea comprising puerh extract as an effective component and process for preparation thereof
JP2003128571A (en) * 2001-10-22 2003-05-08 Matsuura Yakugyo Kk Diabetes medicine and health food
KR100403720B1 (en) * 2002-01-17 2003-11-05 (주)생명의나무 Lower alcohol insoluble extract and a polysaccharide therein isolated from the young branches of hovenia dulcis thunb. having antihepatotoxic, anti-hangover and anti-fatigue activity and composition containing same
WO2003059369A1 (en) * 2002-01-17 2003-07-24 Lifetree Biotech Co., Ltd. Lower alcohol-insoluble extract of hovenia dulcis thunb and a polysaccharide isolated therefrom
KR100403722B1 (en) * 2002-05-09 2003-11-05 Forest Genetis Res Inst Lower alcohol insoluble extract of hovenia dulcis thunberg having liver protection activity, polysaccharide separated therefrom and composition containing the same
KR20020062898A (en) * 2002-07-08 2002-07-31 권만덕 Lindera obtusitoba bl tea
KR100543082B1 (en) * 2003-08-08 2006-01-20 강대식 Manufacturing method of food composition for weight loss and cholesterol reduction

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
WO2009091120A2 (en) 2008-01-18 2009-07-23 Yang Ji Chemical Co., Ltd. Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases
US20110045111A1 (en) * 2008-01-18 2011-02-24 Yang Ji Chemical Co., Ltd. Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases
EP2240193A4 (en) * 2008-01-18 2011-04-27 Yang Ji Chemical Company Ltd Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases
US8734866B2 (en) 2008-01-18 2014-05-27 Yang Ji Chemical Co., Ltd. Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases
CN102665747A (en) * 2009-11-20 2012-09-12 杨智化学（株） Composition for Improving Blood Circulation Containing Santia Cinnamon Extract as Active Ingredient
US20210402323A1 (en) * 2020-06-30 2021-12-30 Henan Zhongda Hengyuan Biotechnology Stock Co., Ltd. Method of preparing hovenia dulcis thunb extract rich in dihydromyricetin
US11642608B2 (en) * 2020-06-30 2023-05-09 Henan Zhongda Hengyuan Biotechnology Stock Co., Ltd. Method of preparing Hovenia dulcis Thunb extract rich in dihydromyricetin

Also Published As

Publication number Publication date
US20090285914A1 (en) 2009-11-19
EP1718167A4 (en) 2010-07-14
JP2007519715A (en) 2007-07-19
US7846484B2 (en) 2010-12-07
EP1718167A1 (en) 2006-11-08
WO2005072758A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
US7846484B2 (en) Composition comprising Hovenia dulcis thunb. extract, Lindera obtusiloba blume extract, or herbal mixture extract thereof
KR101483592B1 (en) Decreasing Effect in Blood Ethanol Concentration and Improvement of Hepatic Function Including Preparation of Sprouts Hordeum Vulgare Extracts
KR101919839B1 (en) Composition for hepatoprotective and ameliorating hangover containing cricket material enzyme-decomposed with Alcalase
US20170035725A1 (en) Muscle atrophy inhibitor
CN101766274B (en) Antioxidant functional food composition containing bamboo leaf flavonoids
KR101688002B1 (en) Composition for preventing or treating liver diseases comprising sonicated ginseng berry
KR101277266B1 (en) A composition comprising of a sprout extract of Triticum aestivum for treating and preventing obesity disease
KR20240015980A (en) A composition for preventing, improving and treating of diabetes comprising extract of pepper leaves and extract of Helianthus tuberosus as effective component
CN1913910B (en) Composition comprising Hovenia dulcis Hoveniae extract, Sanya Aconitum extract, or herbal mixture extracts thereof
KR20250001358A (en) Composition for preventing, improving or treating diabetes comprising Petasites japonicus extract(HL-ADB complex) as an active ingredient
JP6719953B2 (en) Food and drink containing tomatoside A for suppressing blood sugar elevation
US20060210659A1 (en) Anti-obesity agent
KR20190053108A (en) A composition comprising the complex extract for antiobesity of men
KR101154031B1 (en) Composition for Antifati gue containin g herbal mixture extract as in gredient compounds
KR20130056940A (en) Compositions for preventing and treating diabetes or diabetic complications comprising extracts of acer tegmentosum maximowoca and magnolia officinalis rehd. et wils
KR20180079920A (en) Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract
KR20230139872A (en) Composition for preventing or treating liver-related diseases comprising ginger juice as an active ingredient
KR20050090867A (en) Composition comprising schizandrae fructus extract for treatment of diabetes
KR100536856B1 (en) Composition comprising herbal mixture extract
KR20210157522A (en) Composition for preventing, ameliorating or treating diabetic nepropathy comprising bangpungtongseongsan extract as effective component
KR100536855B1 (en) Composition comprising Hovenia dulcis Thunb. extract for improvement of kidney function
JP2002029984A (en) Oral composition
JP2003342187A (en) New liver injury inhibitor
KR101164908B1 (en) The composition for the treatment of cancers or inhibition of metastasis containing the extracts or fractions of Asparagus cochinchinensis as active ingredient
KR20260045087A (en) A composition for improving, preventing and treating of diabetes mellitus comprising barley sprout ultrasonic extract

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION